

Contents

Volume 21, 1987

Volume 21, Number 1

1987

CONTENTS

Special Issue: Adverse Events

- | | | |
|---|----|---|
| Allen Cato
Robert Temple | 1 | Foreword and Acknowledgments |
| Allen Cato | 3 | Premarketing Adverse Drug Experiences:
Data Management Procedures. Unexpected
Death Occurring Early in Clinical Trials |
| Robert T. O'Neill | 9 | Statistical Analyses of Adverse Event Data
from Clinical Trials. Special Emphasis
on Serious Events |
| Karl E. Peace | 21 | Design, Monitoring, and Analysis Issues
Relative to Adverse Events |
| Michael Weintraub
Gerald Ginsberg | 29 | Evaluating Liver Enzyme Abnormalities in
Clinical Trials Involving Diabetic Patients |
| Dorothy B. Windhorst
Edward F. C. Pun
Lonni A. Zubkoff | 39 | Data on Drugs and Adverse Experiences:
Moving from the Specific to the General |
| Ursula Gundert-Remy | 47 | European View Toward Incorporating Adverse
Events into Package Inserts |
| Joel Morganroth | 51 | Remote Data Entry and the Electronic New Drug
Application: An Integrated Approach to Acquire,
Analyze, and Review New Drug Data |
| Noel R. Mohberg | 55 | Some Observations on the Collection of Medical
Event Data |
| Judith Kramer Littlejohn | 63 | Package Insert: View of a Rural Town
Practitioner |

(Contents continued on next page)

A Primer on Postmarketing Surveillance

69 Editor's Note

71 Preface

HISTORICAL PERSPECTIVE

76 FDA Regulation of New Drugs

78 History of Postmarketing Surveillance in the United States

80 The Approach in Great Britain

83 Current Focus on Postmarketing Surveillance

83 Postmarketing Surveillance Activities of the FDA

83 Phase IV Studies

85 Summary of Industry Sponsored Phase IV Studies

EXECUTIVE BRIEF

93 Methods of Postmarketing Surveillance

95 Outline of Postmarketing Surveillance

99 Glossary of Postmarketing Surveillance Terms

BIBLIOGRAPHY

105 Pharmaco-Epidemiology Selected Bibliography

I Software Survey Section:

PATH/TOX SYSTEM

RLAB PC LIMS

BALANCE

MODEL 2600 CHROMATOGRAPHY DATA

ACQUISITION

CAPTURE!

*SIPHAR: INTEGRATED COMPUTER SYSTEM
FOR PHARMACOKINETIC DATA ANALYSIS*

SIGNWRITER (Instant Display Lettering)

PAPERBASE DELUXE

THE KEY

*MEGASOURCE INVESTIGATIONAL DRUG
TRACKING SYSTEM*

MKMODEL

CONTENTS

- | | | |
|------------------------------|-----|---|
| Stuart L. Nightingale | 109 | Regulatory Overview: Protection of Human Subjects—IRBs and Informed Consent |
| Gurston Turner | 117 | FDA's Conduct, Review, and Evaluation of |
| Alan B. Lisook | | Inspections of Clinical Investigators |
| Dana P. Delman | | |
| Thomas J. Kirsch | 127 | The Interrelationships of Sponsors, Clinical Investigators, and Institutional Review Boards |
| Thomas H. Perez | 133 | Adverse Drug Reaction Reporting: Comparison of Reports Received by a Specialized Registry and the Food and Drug Administration System |
| Joel N. Kuritsky | | |
| Gerald A. Faich | | |
| Robert S. Stern | 137 | Spontaneous Adverse Drug Reporting: Do Numbers Tell the Story? |
| Raymond H. Farman | 141 | Management of Pharmacokinetic Data Using HP-3357/Mainframe IBM Interfacing |
| Judi F. Muniak | | |
| Kenneth A. Pittman | | |
| Melvin P. Fisher | 153 | Preparation and Maintenance of Prescription Drug Labeling |
| Ann Summerfelt | 159 | Implementation of Clinical Trials: Simple, but Not Easy |
| Frank R. Funderburk | | |
| G. Edward Collins | 165 | An Integrated Approach for Processing Information Inquiries at the Time of a New Product Launch |
| Cathy S. Frieden | | |
| Gilles Cloutier | | |
| Allen Cato | | |
| Seymour Fisher | 173 | Detecting Adverse Drug Reactions in Postmarketing Surveillance: Interview Validity |
| Stephen G. Bryant | | |
| Ronica M. Kluge | | |
| Daniel E. Klingler | 185 | A Drug Safety Evaluation On-Line Study Log |
| Elizabeth H. Brown | 193 | Standard Operating Procedures for Computer Systems Validation |
| Leonard T. Sigell | 201 | The Role of Drug Information Centers with Consumers |
| J. Frank Bonfiglio | | |
| Earl G. Siegel | | |
| Edwin A. McCray | | |
| Gaylene B. Tsipis | | |

- | | | |
|--|-----|---|
| Freya F. Hermann
Lee A. Wanke | 209 | Analysis and Control of Costs Associated with Answering Drug Information Requests |
| Paula Botstein | 217 | Criteria for Approval of Controlled-Release Products |
| Sanford A. Miller
Frank Edward Scarbrough | 221 | Foods as Drugs |
| Ara Der Marderosian | 229 | Overview of the Use of Food/Natural Products as Drugs |
| Norman R. Farnsworth | 245 | International Perspectives Regarding the Use of Food/Natural Products as Drugs |
| | I | Software Survey Section |
| | | <i>Sci-Mate Software System V2.0</i> |
| | | <i>Chromatography Software for the HP-1000-A Series Computer</i> |
| | | <i>RLAB II</i> |
| | | <i>2600 Chromatography Software for the IBM PC and Compatibles</i> |

CONTENTS

- | | | |
|--|-----|---|
| Gerald A. Faich
Julie B. Milstien
Charles Anello
Carlene Baum | 251 | Sources of Spontaneous Adverse Drug Reaction Reports Received by Pharmaceutical Manufacturers |
| Carlene Baum
Gerald A. Faich
Charles Anello
Mary B. Forbes | 257 | Differences in Manufacturer Reporting of Adverse Drug Reactions to the FDA in 1984 |
| Stefan H. Unger | 267 | Computer-Aided Drug Design in the Year 2000 |
| Robert A. Michalak | 277 | Investigational Adverse Experience Reporting |
| Daniel E. Klingler | 283 | Documentation and Management of Configurable Software |

- C. A. Metz** 289 Development of a Training Program for
G. D. Gutknecht New Clinical Research Personnel
J. C. Schneider
A. Q. Sheridan
C. J. Cross
T. C. Vandermeulen
K. P. Chapman
J. P. Keelan
W. Veldkamp
- Erika F. Nissman** 295 The Use of COSTART at Burroughs
Wellcome Company
- Fred Schneiweiss** 299 Adverse Reaction Thesauri Used in the
Pharmaceutical Industry
- Fiona M. Cunningham** 303 QA Report Auditing: A Procedure for Selecting and
Kevin J. Gough Identifying Data Points for Checking
- Nancy Mattison** 309 Postapproval Research Requested by the FDA at the
Barbara W. Richard Time of NCE Approval, 1970-1984
- Bart Holland** 331 Monitoring Adverse Drug Reactions Using a
Steven Marcus State Poison Control Center Data Base
- Alan M. Saltzman** 335 A MIS System for Worldwide Acquisition of Remote
Clinical Information
- G. James Davis** 353 The Successful Development Team: A Case Study
Daniel R. Klingler
- Theresa E. Stokes** 361 Clinical Data Management and Remote Data Entry
- Frederick H. Fern** 367 Dual Regulatory Pharmaceutical Labeling Schemes:
Lewis Bartell The Role of the Federal Preemption Doctrine
- I Software Survey Section:
CALS PEAKPRO
CALS LAB MANAGER

CONTENTS

- Craig E. Hammes** 377 Foreword and Acknowledgements
- William E. Gilbertson** 379 FDA OTC Drug Standards Versus Cosmetic
Standards

Heinz J. Eiermann	387	Regulatory Requirements for Marketing Cosmetics in the United States
Paul M. Hyman	393	Regulatory Risks of Marketing Drugs and Cosmetics
C. L. Hagenbush	403	Practical and Theoretical Distinctions Between Drugs and Cosmetics
Ann H. Wion	409	Legal Perspective — OTC Drugs and Cosmetics
Elizabeth B. D'Angelo	417	Foreword and Acknowledgements
William J. Meddick	419	Computer Systems Validation: Dollars and Sense
Daniel E. Klingler	431	The Role of Rapid Prototypes in Software Validation
Daniel Shirley	441	Software Validation Strategies for Clinical Trials Systems
Graham Martin J. Tony Wildsmith	445	A New Approach to Error Reduction in the Acquisition and Delivery of Analytical Laboratory Data
Thomas J. Ott Stephen A. Herczeg Robert K. Campbell	455	Quality Assurance of Clinical Data in a Remote Data Entry Environment
Will Anderson	461	Software Validation Techniques
D. C. Mattes B. J. Clark	471	Development of Systematic Data Access and Integrity Features for Pharmaceutical Computer Applications
Jay Herson	475	Validation of Database Management System Applications for Clinical Trials
Jonathan S. Kahan	481	Legal Implications of Software Validation
Maryanne Malone	487	Managing the Validation Process
J. C. Lynch M. A. Schreiber	495	Documentation and Validation of a User Writer Program
Michael Todd Roger Landau Theodore Koziol Robert Dwyer Kim Nitahara	503	Validation of the Bioanalytical Computer Systems

517 Index to Volume 21, 1987

- I Software Survey Section:
 - ILEUM ver. 2.0*
 - CARDIOLAB*
 - Compudex*